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Association of neurotensin toits receptor in HT29 cells increases the intracellular concentration f inositol 
phosphates. A rapid (20-30 s), transient stimulation of inositol trisphosphate (275% of the basal evel) and 
inositol bisphosphate (420%) is first observed, followed by a slower, stable increase in inositol monophos- 
phate (170%). Half-maximal stimulation ofthe three inositol phosphates was obtained with 50-100 nM neu- 
rotensin. These results indicate that neurotensin is able to regulate intracellular tCa2+ levels in HT29 cells 
by using inositol trisphosphate as a second messenger. 
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1. INTRODUCTION 
The pharmacological and biochemical proper- 
ties of neurotensin (pGlu-Leu-Tyr-Glu-Asn-Lys- 
Pro-Arg-Arg-Pro-Tyr-Be-Leu) strongly suggest 
that the peptide acts as a neurotransmitter or 
neuromodulator in the central nervous system [l] 
and as a hormone in the periphery [2]. Specific 
neurotensin receptors have been characterized not 
only in brain and gastrointestinal membrane 
preparations but also in intact cells of neural or 
nonneural origin [3). We have recently taken ad- 
vantage of the presence of high-affinity neuroten- 
sin binding sites in the electrically excitable 
neuroblastoma NlEl15 clone [4] to study the in- 
tracellular consequences of neurotensin receptor 
occupancy in a model nerve cell. We found that 
association of neurotensin to its neuroblastoma 
receptor increased the basal cGMP level by a fac- 
tor of 10 [5] and decreased the prostaglandin 
El-stimulated CAMP concentration by 55% [6]. 
The neurotensin-induced cGMP stimulation has 
also been reported by others [7]. 
The purpose of this work was to identify the in- 
tracellular events that are regulated by neurotensin 
receptors in a nonneural cell line. Since neuroten- 
sin had previously been shown to interact with 
specific receptors in the human colonic adenocar- 
cinema HT29 [8], this clone was used as a model 
of nonneural target cell. We show that neurotensin 
has little effect on cyclic nucleotide levels in HT29 
cells but strongly stimulates phosphatidylinositol 
turnover according to a receptor-mediated 
mechanism. 
* To whom correspondence should be addressed 2. MATERIALS AND METHODS 
Abbreviations: TPA, 4&phorbol 12-myristate 13- 
acetate; IPr, inositol monophosphate; IP2, inositol 
bisphosphate; IPs, inositol trisphosphate 
2.1. Drugs and peptides 
Z-pro-prolinal (N-benzyloxycarbonyl-prolyl- 
prolinal) was kindly provided by Dr S. Wilk 
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(Department of Pharmacology, Mount Sinai 
School of Medicine, NY). 1, IO-Phenanthroline 
was from Merck; 4&phorbol 12-myristate 
13-acetate (PMA) from Sigma. myo-[2-3H]Inositol 
(Amersham, 12.3 Ci/mmol) was purified before 
use by chromatography on a Dowex 1 x 8 column 
(0.8 ml, formate form) eluted with HzO. 
Neurotensin, neurotensin (1- 12), acetylneuroten- 
sin (8-13) and neurotensin (9-13) were generous 
gifts from Drs C. Granier and J. Van Rietschoten 
(Faculte de Medecine Nord, Marseille, France). 
[Monoiodo-Tyr3]neurotensin (2000 Ci/mmol) was 
prepared and purified as described [9]. 
2.2. Cell culture 
The HT29 cell line kindly provided by Dr J. 
Fogh (Sloan Kettering Institute, Rye, NY) was 
cultured in 75 cm2 Falcon tissue culture flasks at 
37°C in Dulbecco’s modified Eagle’s medium sup- 
plemented with 10% fetal calf serum, penicillin 
(50 U/ml) and streptomycin (50 ,ug/ml), in a 
humidified atmosphere of 5% CG2/95% air. Cells 
used in binding and biochemical experiments 
(passages 13-26) were obtained as follows: cells 
were detached before confluence by incubation for 
5 min in a 10 mM phosphate buffer containing 
140 mM NaCl, 5 mM KCl, 50 PM EDTA and 
0.02% trypsin. After centrifugation, the cellular 
pellet was washed and resuspended in 10 ml 
culture medium. The number of viable cells was 
determined by trypan blue exclusion. The cell 
suspension was distributed into Falcon 24-wells 
plates (-10’ cells/well) and allowed to grow for 
3-5 days before use. 
2.3. Binding experiments 
Monolayers of HT29 cells (5 x 105-8 x lo5 
cells/well) were incubated at 37°C with various 
concentrations of *2’I-labeled [monoiodo-Tyr3]- 
neurotensin and unlabeled neurotensin or its 
analogues in a total volume of 200 ~1 incubation 
buffer (25 mM Hepes-Tris, pH 7.4, containing 
140 mM NaCI, 5 mM KCl, 1.8 mM CaC12, 
0.9 mM MgCl2, 0.02% bovine serum albumin, 
4.5 g/l glucose, 1 mM l,lO-phenanthroline and 
0.1 PM Z-pro-prolinal). After 30 min of incuba- 
tion, the medium was removed by aspiration and 
the cell layer was rapidly washed twice with 0.5 ml 
of incubation buffer. Cells were detached with 
1 ml of 0.1 M NaOH and the radioactivity bound 
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to the cells was counted with an Intertechnique CG 
4000 gamma counter at a counting efficiency of 
80%. Nonspecific binding was determined in the 
presence of 1 PM unlabeled neurotensin and sub- 
tracted from total binding to obtain the specific 
binding. 
2.4. Cyclic nucleotide measurements 
HT29 cells were incubated at 37°C for different 
times with or without neurotensin (0.1-l PM) in 
200~1 of the buffer used in binding experiments. 
The CAMP and cGMP content of cell extracts was 
measured as described for neuroblastoma NlEl15 
cells [5]. 
2.5. Labeling of HT29 cells with PH]inositol and 
measurement of phosphatidylinositol 
turnover 
Cell monolayers (5 x 105-8 x 10’ cells/well) 
were incubated for 18 h at 37°C with 1 ml of 
serum-free culture medium containing 3 &i 
[3H]inositol. After extensive washing, cells were 
preincubated for 15 min at 37°C with 200~1 of a 
25 mM Hepes-Tris buffer, pH 7.4, containing 
110 mM NaCI, 5 mM KCI, 1.8 mM CaCl2, 
0.9 mM MgC12, and 30 mM LiCl in order to in- 
hibit inositol-1 -phosphatase [lo]. Stimulation of 
phosphatidylinositol hydrolysis was initiated by 
addition of a 20~1-aliquot of peptide solution to 
the incubation medium. The reaction was ter- 
minated by aspiration of the medium and the cell 
layer in each well was extracted with 300 ~1 of 10% 
perchloric acid for 15 min at 4°C then washed 
once with 300~1 H20. Combined extracts were 
buffered with 75 mM Hepes and neutralized with 
2 M KOH. The KC104 precipitate was removed by 
centrifugation and supernatants were analyzed for 
their inositol phosphate content according to the 
technique described by Bone et al. [ 111. Briefly, 
soluble extracts were applied to columns (0.8 ml) 
of Dowex-1 x 8 (formate form; BioRad) that were 
eluted stepwise by solutions containing increasing 
concentrations of formate. Fractions were col- 
lected in the following order: free inositol(6 ml of 
water); glycerophosphoinositol (6 ml of 5 mM 
sodium tetraborate/60 mM ammonium formate); 
IPr (8 ml of 5 mM sodium tetraborate/200 mM 
ammonium formate); IP2 (6 ml of 0.1 M formic 
acid/O.5 M ammonium formate); and IP3 (6 ml of 
0.1 M formic acid/l.5 M ammonium formate). 
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The radioactivity of each fraction was counted 
after addition of 15 ml Aquassure (New England 
Nuciear). 
3. RESULTS 
3.1 .Binding properties of neurotensin receptors in 
monolayers of HT29 celis 
Neurotensin receptors in HT29 cell suspension 
have already been characterized at 24’C with 
j3H]neurotensin as labeled ligand [8]. Since in- 
tracellular responses to neurotensin were studied at 
37°C and with plated HT29 cells, the binding 
properties were reinvestigated under these condi- 
tions using [monoiodo-Tyr3]neurotensin as labeled 
ligand. In order to protect neurotensin and its 
analogues from extensive degradation by cell pro- 
teases, binding experiments were carried out in the 
presence of 1, lo-phenanthroline, a metallopep- 
tidase inhibitor [12], and of 0.1 PM Z-pro- 
prolinal, a specific inhibitor of proline endopep- 
tidase [13]. These two inhibitors reduced the 
amount of neurotensin degraded by HT29 cells in 
the course of binding experiments (30 min at 37%) 
from about 80% to less than 5%. 
The binding and biological properties of 
[monoiodo-Tyr3]neurotensin are identical to those 
of the parent peptide [9]_ It was therefore possible 
to use mixtures of ‘251-labeled [monoiodo- 
Tyr3]neurotensin and native neurotensin to study 
the binding of neurotensin to its cell receptor. 
These radiolabeled peptide preparations associated 
to specific neurotensin binding sites in monolayers 
of HT29 cells according to pseudo first-order 
kinetics (not shown). Binding equilibrium was 
always reached after 30 min of association. Fig. 1A 
shows the results of equilibrium binding ex- 
periments in which radiolabeled neurotensin solu- 
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Fig. 1. Binding of neurotensin and its analogues to monolayers of HT29 cells. (A) Saturation experiments. ‘*?-labeled 
neurotensin solutions of various specific radioactivities were prepared by mixing ‘251-labeled [monoiodo- 
Tyr’lneurotensin with unlabeled neurotensin. HT29 cells were incubated with increasing concentrations of ‘251-labeled 
neurotensin in the presence (nonspecific binding, 0) or absence (total binding, not shown) of 1 pM unlabeled 
neurotensin. Specific binding (of is the difference between total and nonspecific binding. A Scatchard plot of the data 
is presented in the inset. B and F are the bound and free concentrations of labeled neurotensin. (3) Competition 
experiments. 12’I-labeled [monoiodo-Tyr’lneurotensin ([lz51 Tyr3]NT, 0.15 nM) was incubated with HT29 cells and the 
indicated concentrations of unlabeled neurotensin (o), acetylneurotensin (8-13) (0), neurotensin (9-13) (0) or 
neurotensin (I-12) (a). In both saturation and competition experiments the radioactivity bound to cells was measured 
after incubation for 30 min at 37°C. Each point represents he mean of sextuplicate determinations from 3 different 
experiments. 
33 
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tions of increasing concentration were incubated 
with a constant number of HT29 cells. The specific 
binding is saturable whereas the nonspecific 
binding increases linearly with the peptide concen- 
tration. Linearity of the Scatchard plot (inset of 
fig. IA) demonstrates that neurotensin associates 
with a single class of noninteracting binding sites. 
The dissociation constant of the neurotensin- 
receptor complex is 1.2 nM and the maximal 
binding capacity of HT29 cells is 45 fmol of pep- 
tide bound per lo6 cells. 
The affinity of neurotensin for its cell receptor 
was compared to those of three neurotensin 
analogues in competition experiments involving 
various concentrations of unlabeled peptides and 
constant amounts of cells and ‘251-labeled 
[monoiodo-Tyr3]neurotensin (fig. 1B). The dis- 
sociation constant of the complex formed between 
native neurotensin and its receptor calculated from 
these data [5] was 1.5 nM, a value not significantly 
different from that found in saturation experi- 
ments (fig.lA). This result confirms that [mono- 
iodo-Tyr3]neurotensin and native neurotensin bind 
to the same receptor with identical properties. The 
affinity of acetyl neurotensin (8-13) was also very 
similar to that of neurotensin whereas that of 
neurotensin (9-13) was about 200-times lower. 
The dissociation constant of neurotensin (1- 12) 
was not determined since this analogue displaced 
the bound radiolabeled ligand by less than 20% at 
1 PM. 
3.2. Effect of neurotensin on intracellular cyclic 
nucleotide levels in HT29 cells 
Neurotensin was found to have no effect on the 
basal concentration of both CAMP and cGMP in 
HT29 cells, even at concentrations as high as 
1 PM. The inability of neurotensin to modulate 
CAMP levels in this cell line has already been 
reported [ 141. 
3.3. Stimulation of inositol phosphate levels by 
neurotensin in HT29 cells 
Water-soluble extracts of HT29 cells prelabeled 
with [3H]inositol contained five 3H-labeled inositol 
derivatives that could be separated by anion ex- 
change chromatography [111. The first two eluted 
fractions were free inositol, which represented 
more than 90% of the water-soluble radioactivity, 
and glycerophosphoinositol which was weakly 
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radiolabeled. The intracellular concentrations of 
these two compounds were insensitive to neuroten- 
sin. By contrast, incubation of HT29 cells with 
0.1 ,DM neurotensin in the presence of Li+ pro- 
duced a rapid and transient stimulation of IPs and 
IP2 levels, and a slower, more persistent increase of 
the IPi concentration (fig.2). Maximal responses 
were obtained after 20 s, 30 s and 2 min, respec- 
tively. Concentration-response curves for the ef- 
fect of neurotensin on the intracellular levels of 
each one of the three inositol phosphates are 
presented in the main part of fig.3. Maximal 
stimulations over basal levels of 170 (IPi), 420 
(IP2) and 275% (IP3) were observed at 1 pM 
neurotensin. The peptide concentrations that in- 
duced half-maximal effect (ECHO) were similar: 60, 
84 and 87 nM for IPt, IP2 and IP3, respectively. 
6 C 
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Fig.2. Time course of neurotensin-induced stimulation 
of inositol phosphate levels in HT29 cells. Monolayers 
of HT29 cells were prelabeled for 24 h with [3H]inositol, 
then incubated at 37°C in a Hepes buffer, pH 7.4, in the 
presence (0) or absence (0) of 100 nM neurotensin. 
After the indicated incubation times, the IPI (A), IPz (B) 
and IP3 (C) cell contents were measured by ion-exchange 
chromatography [ll]. Each point is the mean of 
sextuplicate determinations from 3 different experi- 
ments. 
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Three neurotensin partial sequences were com- 
pared to the parent peptide for their ability to 
stimulate IPJ formation (inset of fig.3). Neuroten- 
sin (1- 12) was totally inactive, even at a concentra- 
tion of 1 pM. Acetylneurotensin (8-13) was very 
similar to native neurotensin in terms of both effi- 
ciency (260% stimulation of the basal level) and 
potency (EC50 = 63 nM). Neurotensin (9-13) did 
not produce maximal stimulation at the highest 
concentration assayed (1 PM); its EC& value was 
500 nM. Similar relative potencies of neurotensin 
and its analogues, i.e. acetylneurotensin (8-13) 2 
neurotensin > neurotensin (9-13) & neurotensin 
(1-12) = 0, were obtained for stimulation of IPi 
and IP2 (not shown). 
Preincubation of cells with PMA, a phorbol 
ester which activates protein kinase C, resulted in 
a drastic attenuation of the neurotensin-promoted 
stimulation of inositol phosphate levels. In the 
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Fig.3. Concentration-response curves for the stimulation 
of inositol phosphate levels induced by neurotensin and 
its analogues in HT29 cells. Cells were prelabeled for 
24 h with [3H]inositol, then incubated at 37°C with the 
indicated concentrations of neurotensin. Intracellular 
inositol phosphate levels were determined after an 
incubation time of 20 s for IP3 (o), 30 s for IP2 (B) and 
2 min for IPi (A). (Inset) [3H]Inositol-prelabeled cells 
were incubated at 37°C with the indicated concentra- 
tions of neurotensin (0). acetylneurotensin (8-13) (0), 
neurotensin (9-13) (v) or neurotensin (1-12) (v). IP3 
levels were determined after an incubation time of 20 s. 
Each point is the mean of sextuplicate determinations 
from 3 different experiments. 
course of three different experiments, the mean 
values of the inhibition percentages induced by 
0.1 /cg/ml PMA against the effect of 0.1 PM 
neurotensin were 72 + 3 (IPl), 82 f 4 (IP2) and 74 
+ 3% (IP3). 
4. DISCUSSION 
The main result of this work is that neurotensin 
stimulates the formation of inositol phosphates in 
HT29 cells, while not affecting CAMP and cGMP 
levels. The rapid and transient increase of IP3 is 
observed just before that of IP2. Both products are 
finally hydrolyzed into IPl which accumulates in- 
side the cell in the presence of Li+ [lo]. This kinetic 
pattern suggests that phosphodiesterase-catalyzed 
hydrolysis of phosphatidylinositol 4,5-bisphos- 
phate into IP3 and diacylglycerol is the major event 
initiated by neurotensin [15- 181. Binding affinities 
of neurotensin and three of its analogues (fig.lB) 
are correlated to their potencies for increasing IP3 
levels (fig.3, inset). Therefore, the intracellular ef- 
fects of neurotensin on phosphatidylinositol 
breakdown in HT29 cells appear to be direct con- 
sequences of neurotensin receptor occupancy. As 
already observed with a variety of other neuroten- 
sin receptors [3], the integrity of the C-terminal 
8-13 peptide sequence is essential for an optimal 
expression of neurotensin activities. 
As far as we are aware, the only other evidence 
of a neurotensin-induced stimulation of phos- 
phatidylinositol turnover has been obtained in rat 
brain slices [19]. In these studies, CAMP levels 
were found to be insensitive to neurotensin; no at- 
tempt was made to investigate the influence of 
neurotensin on cGMP formation. We have demon- 
strated that in neuroblastoma NlE115 cells, the as- 
sociation of neurotensin to its receptor is able not 
only to modulate cyclic nucleotide levels (see sec- 
tion 1) but also to stimulate IP3 formation (in 
preparation). Taken together, these results indicate 
that stimulation of phosphatidylinositol break- 
down is a more general response to neurotensin 
receptor occupancy than modulation of cyclic 
nucleotide levels. 
It has been demonstrated that phorbol esters, 
which mimic diacylglycerol in activating protein 
kinase C, are able to inhibit agonist-induced for- 
mation of inositol phosphates in human platelets 
[20], rat hippocampal slices [21] and DDTl MF-2 
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smooth muscle cells [22]. In this work, we found 
that pretreatment of HT29 cells with PMA 
decreased by more than 70% the ability of 
neurotensin to stimulate levels of the three inositol 
phosphates. This observation is in agreement with 
the suggestion that protein kinase C activation by 
diacylglycerol may be involved in a general feed- 
back inhibition mechanism leading to phos- 
phorylation and inactivation of receptors that are 
coupled to the inositol phospholipid cycle [20-221. 
The pharmacological properties of neurotensin 
on neutrophils [23], smooth muscle [24] or 
pituitary cells [25] have been correlated with the 
ability of the peptide to modulate intracellular 
Ca2+ levels. Similarly, we show here that neuroten- 
sin is also able to mobilize Ca2+ from intracellular 
stores in HT29 cells by using IPJ as a second 
messenger. Since this mechanism also occurs in rat 
brain slices [ 191 and in NlE115 cells (in prepara- 
tion), it may well represent a general mode of 
translation of the neurotensin-receptor interaction 
inside neurotensin target cells of different origin. 
ACKNOWLEDGEMENTS 
This work was supported by the CNRS (ATP 
no.1057), the INSERM (CRE 846021) and the 
Fondation pour la Recherche Medicale. We wish 
to thank M. Bonacci for expert secretarial 
assistance. 
REFERENCES 
[l] Nemeroff, C.B., Luttinger, D. and Prange, A.J. jr 
(1982) in: Neurotensin and Bombesin (Iversen, 
L.L., Iversen, SD. and Snyder, S.H. eds) 
Handbook of Psychopharmacology, vol. 16, 
pp.363-467, Plenum, New York. 
[2] Hirsh Fernstrom, M., Carraway, R.E. and 
Leeman, S.E. (1980) in: Neurotensin (Martini, L. 
and Ganong, W.F. eds) Frontiers in 
Neuroendocrinology, ~01.6, pp.103-127, Raven, 
New York. 
[3] Kitabgi, P., Checler, F., Mazella, J. and Vincent, 
J.P. (1986) Rev. Pure Appl. Pharmacol. Sci., in 
press. 
[4] Poustis, C., Mazella, J., Kitabgi, P. and Vincent, 
J.P. (1984) J. Neurochem. 42, 1@4-1100. 
36 
151 
161 
171 
PI 
[91 
1101 
1111 
1121 
[I31 
1141 
WI 
[I61 
1171 
[I81 
[I91 
PO1 
WI 
WI 
1231 
1241 
PI 
Amar, S., Mazella, J., Checler, F., Kitabgi, P. and 
Vincent, J.P. (1985) Biochem. Biophys. Res. Com- 
mun. 129, 117-125. 
Bozou, J.C., Amar, S., Vincent, J.P. and Kitabgi, 
P. (1986) Mol. Pharmacol., in press. 
Gilbert, J.A., Moses, C. J., Pfenning, M.A. and 
Richelson, E. (1986) Biochem. Pharmacol. 35, 
391-397. 
Kitabgi, P., Poustis, C., Ciranier, C., Van 
Rietschoten, J., Rivier, J., Morgat, J.L. and 
Freychet, P. (1980) Mol. Pharmacol. 18, 11-19. 
Sadoul, J.L., Mazella, J., Amar, S., Kitabgi, P. 
and Vincent, J.P. (1984) Biochem. Biophys. Res. 
Commun. 120, 812-819. 
Hallcher, L.M. and Sherman, W.R. (1980) J. Biol. 
Chem. 255, 10896-10901. 
Bone, E.A., Fretten, P., Palmer, S., Kirk, C.J. and 
Michell, R.H. (1984) Biochem. J. 221, 803-811. 
Checler, F., Vincent, J.P. and Kitabgi, P. (1983) J. 
Neurochem. 41, 375-384. 
Wilk, S. and Orlowski, M. (1983) J. Neurochem. 
41, 67-75. 
Laburthe, M., Rousset, M., Boissard, C., 
Chevalier, G., Zweibaum, A. and Rosselin, G. 
(1978) Proc. Natl. Acad. Sci. USA 75, 2772-2775. 
Akhtar, R.A. and Abdel-Latif, A.A. (1980) 
Biochem. J. 192, 783-791. 
Creba, J.A., Downes, C.P., Hawkins, P.T., 
Brewster, G., Michell, R.H. and Kirk, C.J. (1983) 
Biochem. J. 212, 733-747. 
Berridge, M.J., Dawson, R.M.C., Downes, C.P., 
Heslop, J.P. and Irvine, R.F. (1983) Biochem. J. 
212, 473-482. 
Berridge, M.J. and Irvine, R.F. (1984) Nature 312, 
315-321. 
Goedert, M., Pinnock, R.D., Downes, C.P., 
Mantyh, P.W. and Emson, P.C. (1984) Brain Res. 
323, 193-197. 
Watson, S.P. and Lapetina, E.G. (1985) Proc. 
Natl. Acad. Sci. USA 82, 2623-2626. 
Labarca, R., Janowsky, A., Patel, J. and Paul, 
S.M. (1984) Biochem. Biophys. Res. Commun. 
123, 703-709. 
Leeb-Lundberg, M.F., Cotecchia, S., Lomasney, 
W.J., De Bernardis, J.F., Lefkowitz, R.J. and 
Caron, M.G. (1985) Proc. Natl. Acad. Sci. USA 
82, 5651-5655. 
Goldman, R., Bar-Shavit, Z. and Romeo, D. 
(1983) FEBS Lett. 159, 63-67. 
Kitabgi, P. (1982) Ann. NY Acad. Sci. 400, 37-53. 
Memo, M., Carboni, E., Trabucchi, M., Carruba, 
M.O. and Spano, P.F. (1985) Brain Res. 347, 
253-257. 
